Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Author information

1
Cancer Research, Global Pharmaceutical R&D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6101, USA. milan.bruncko@abbott.com

Abstract

A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.

PMID:
15582418
DOI:
10.1016/j.bmcl.2004.10.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center